“Frank” Talk On Drug Pricing: HHS Official Sees Value-Based Pricing As Area Of Common Interest
This article was originally published in RPM Report
The most likely next step in executive branch action on drug pricing will be testing approaches to value-based pricing in categories where pharmaceutical companies are willing participants. That appears to be the message from an HHS official speaking at a DC policy event.
Register for our free email digests: